AN-7 - CAS 213262-83-0
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Publictions citing BOC Sciences Products
  • >> More
AN-7; butyroyloxymethyl diethylphosphate
Current Developer:
Tel Aviv University.
1.The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
Moyal L1,2, Feldbaum N1, Goldfeiz N1, Rephaeli A3, Nudelman A4, Weitman M4, Tarasenko N3, Gorovitz B1, Maron L1, Yehezkel S1, Amitay-Laish I2, Lubin I5, Hodak E1,2. PLoS One. 2016 Jan 11;11(1):e0146115. doi: 10.1371/journal.pone.0146115. eCollection 2016.
The 2 histone deacetylase inhibitors (HDACIs) approved for the treatment of cutaneous T-cell lymphoma (CTCL) including mycosis fungoides/sezary syndrome (MF/SS), suberoylanilide hydroxamic acid (SAHA) and romidepsin, are associated with low rates of overall response and high rates of adverse effects. Data regarding combination treatments with HDACIs is sparse. Butyroyloxymethyl diethylphosphate (AN-7) is a novel HDACI, which was found to have selective anticancer activity in several cell lines and animal models. The aim of this study was to compare the anticancer effects of AN-7 and SAHA, either alone or combined with doxorubicin, on MF/SS cell lines and peripheral blood lymphocytes (PBL) from patients with Sezary syndrome (SPBL). MyLa cells, Hut78 cells, SPBL, and PBL from healthy normal individuals (NPBL) were exposed to the test drugs, and the findings were analyzed by a viability assay, an apoptosis assay, and Western blot. AN-7 was more selectively toxic to MyLa cells, Hut78 cells, and SPBL (relative to NPBL) than SAHA and also acted more rapidly.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Chemical Structure

CAS 213262-83-0 AN-7

Quick Inquiry

Verification code

Featured Items